Alx Oncology Holdings (ALXO) Gains from Investment Securities (2021 - 2026)
Alx Oncology Holdings recorded quarterly Gains from Investment Securities of $307000.0 in Q1 2026, up 36.44% quarter-over-quarter from $225000.0 in Q4 2025, and little changed year-over-year from $307000.0 in Q1 2025.
Alx Oncology Holdings' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at $307000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities changed 0.0% year-over-year to $307000.0; the TTM figure through Mar 2026 stood at $929000.0 (down 66.0% YoY), while the FY2025 annual figure was $12.9 million, up 22.31% from the prior year.
- Gains from Investment Securities came in at $307000.0 for Q1 2026 at Alx Oncology Holdings, up from $225000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.8 million in Q4 2024 to a low of -$799000.0 in Q4 2023.
- A 5-year average of $343820.6 and a median of $225000.0 in 2025 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities tumbled 846.73% in 2023 and soared 331.41% in 2024, its largest moves.
- Alx Oncology Holdings' Gains from Investment Securities stood at $107000.0 in 2022, then sank by 846.73% to -$799000.0 in 2023, then soared by 331.41% to $1.8 million in 2024, then slumped by 87.83% to $225000.0 in 2025, then jumped by 36.44% to $307000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $307000.0, $225000.0, and $160000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 307,000.00 |
| Mar 31, 2026 | 307,000.00 |
| Dec 31, 2025 | 225,000.00 |
| Dec 31, 2025 | 225,000.00 |
| Sep 30, 2025 | 160,000.00 |
| Sep 30, 2025 | 160,000.00 |
| Jun 30, 2025 | 237,000.00 |
| Jun 30, 2025 | 237,000.00 |
| Mar 31, 2025 | 307,000.00 |
| Mar 31, 2025 | 307,000.00 |
| Dec 31, 2024 | 1.85 Mn |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 358,000.00 |
| Sep 30, 2024 | 358,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Dec 31, 2023 | -799,000.00 |
| Dec 31, 2023 | -799,000.00 |
| Sep 30, 2023 | 973,000.00 |
| Sep 30, 2023 | 973,000.00 |
| Jun 30, 2023 | 107,000.00 |
| Jun 30, 2023 | 107,000.00 |
| Mar 31, 2023 | 107,000.00 |
| Mar 31, 2023 | 107,000.00 |
| Dec 31, 2022 | 107,000.00 |
| Dec 31, 2022 | 107,000.00 |
| Sep 30, 2022 | 904,750.00 |
| Sep 30, 2022 | 904,750.00 |
| Jun 30, 2022 | 504,200.00 |
| Jun 30, 2022 | 504,200.00 |
| Mar 31, 2022 | 105,000.00 |
| Mar 31, 2022 | 105,000.00 |
| Dec 31, 2021 | 104,000.00 |
| Dec 31, 2021 | 104,000.00 |
| Sep 30, 2021 | -1.64 Mn |
| Sep 30, 2021 | -1.64 Mn |